[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-rhinitis-ar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-rhinitis-ar":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,75,99,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100641031","effect-of-ayurveda-treatment-in-allergic-rhinitis-100641031",false,"NCT07626099","EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS","EFFECT OF AN AGNI-MODULATING AYURVEDIC INTERVENTION ON GUT PERMEABILITY AND TH2-MEDIATED IMMUNE BIOMARKERS IN ALLERGIC RHINITIS: A RANDOMIZED CONTROLLED TRIAL PROTOCOL","ARAM","\\*\\*Inclusion Criteria:\\*\\*\n\n* Participants aged 18-40 years.\n* Clinical diagnosis of Allergic Rhinitis based on standard diagnostic criteria.\n* Positive skin prick test to relevant allergens.\n* Presence of active allergic rhinitis symptoms at the time of recruitment.\n* Willingness to participate and provide written informed consent.\n* Willingness to comply with study procedures, laboratory investigations, and follow-up assessments.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Severe systemic illness.\n* Immunodeficiency disorders.\n* Autoimmune diseases.\n* Chronic gastrointestinal disorders that may influence gut permeability parameters.\n* Other chronic inflammatory conditions that may influence immune response.\n* Long-term immunosuppressive therapy.\n* Systemic corticosteroid therapy.\n* Biologic therapy.\n* Use of medications known to significantly alter immune response or gut microbiota.\n* Use of antibiotics within the previous 3 months.\n* Use of probiotics within the previous 3 months.\n* Use of prebiotics within the previous 3 months.\n* Pregnancy.\n* Lactation.\n* Known food allergy or hypersensitivity to study medications.\n* Severe psychiatric illness.\n* Inability to comply with study procedures.\n* Current participation in another clinical trial.","ALL","16 Years","40 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background Allergic Rhinitis is a chronic Th2-mediated inflammatory disorder associated with significant disease burden and impaired quality of life. Emerging evidence highlights the role of the gut-immune axis, intestinal permeability, and microbial-metabolic signaling in modulation of allergic immune responses. In , Agni is considered the fundamental regulator of digestion, metabolism, and physiological homeostasis. Disturbance in Agni may contribute to altered gut homeostasis and immune dysregulation. However, the relationship between Agni, gut permeability-associated mechanisms, and Th2-mediated immune response in allergic rhinitis remains insufficiently explored.\n\nAim To evaluate the effect of an Agni-modulating Ayurvedic intervention on Th2-mediated immune response and gut permeability-associated mechanisms in individuals with allergic rhinitis.\n\nObjectives The primary objective is to evaluate the effect of an Agni-modulating Ayurvedic intervention on serum immunoglobulin E (IgE) and interleukin-4 (IL-4) levels in allergic rhinitis. Secondary objectives include assessment of gut permeability-associated biomarkers including serum zonulin and lactulose-mannitol test parameters, evaluation of changes in Agni status and clinical symptom severity, and exploration of associations between Agni status, gut permeability-associated biomarkers, and immune response. The study also aims to explore inter-individual variability based on Agni types and Prakriti.\n\nMethods This study is designed as a randomized, controlled, assessor-blinded, parallel-group clinical trial with an embedded exploratory mechanistic component. A total of 104 participants aged 18-60 years diagnosed with allergic rhinitis based on standard clinical criteria and positive skin prick test will be recruited and randomized in a 1:1 ratio into intervention and control groups. The intervention group will receive a standardized Agni-modulating Ayurvedic treatment protocol consisting of Deepana-Pachana formulations followed by Amrita Ghritham along with Pathya-Apathya advice, in addition to standard conventional management. The control group will receive standard conventional management. Primary outcome measures include serum IgE, IL-4, serum zonulin, and lactulose-mannitol test parameters. Secondary outcomes include Agni assessment, Total Nasal Symptom Score (TNSS), eosinophil count, and subgroup analysis based on Agni and Prakriti.\n\nExpected Outcome The study is expected to provide preliminary evidence regarding the relationship between Agni modulation, gut permeability-associated mechanisms, and Th2-mediated immune response in allergic rhinitis, and may contribute to biomarker-oriented translational and integrative approaches in allergic disease management.",[28],"Allergic Rhinitis (AR)",[30,31,32,33,34,35,36,37],"allergic rhinitis","agni","ayurveda","gut-immune axis","Th2 immunity","IgE","Serum Zonulin","Lactose-Mannitol test","NOT_YET_RECRUITING","2026-05-29",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":22},"2028-06-30",{"date":46,"type":22},"2030-12-30",{"name":48,"class":49},"Amrita Vishwa Vidyapeetham","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100634265","evaluation-of-the-adjunctive-effects-of-moxibustion-in-the-treatment-of-cold-syndrome-allergic-rhinitis-100634265","NCT07537439","Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic Rhinitis","Evaluation Of The Adjunctive Effects Of Moxibustion In The Treatment Of Cold-Syndrome Allergic Rhinitis","Inclusion Criteria:\n\n* Adults aged 18 to 60 years.\n* Diagnosed with allergic rhinitis according to ARIA guidelines.\n* Presence of typical nasal symptoms such as sneezing, rhinorrhea, nasal obstruction, or nasal itching.\n* Classified as cold-related syndrome according to traditional medicine assessment.\n* Indicated for treatment with intranasal corticosteroids.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals.\n* Severe nasal structural abnormalities or nasal polyps.\n* History of asthma or other significant chronic respiratory diseases.\n* Known allergy or intolerance to moxibustion smoke or study medications.\n* Severe comorbid medical conditions that may interfere with study participation.\n* Inability to comply with study procedures.","18 Years","60 Years",{"count":60,"type":22},60,[25],"Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa characterized by one or more of the following symptoms: nasal obstruction, rhinorrhea, sneezing, and nasal itching. It is an IgE-mediated immune disorder that typically occurs after exposure to allergens such as pollen, house dust mites, and animal dander. The reported prevalence of rhinitis in adults ranges widely from 1% to over 60%, largely depending on diagnostic definitions and geographic regions. Allergic rhinitis is estimated to affect approximately 10% to 30% of the global population and imposes a substantial burden on sleep quality, quality of life, cognitive function, and work productivity.\n\nDue to its chronic course, frequent recurrence, and complex pathophysiology, allergic rhinitis not only adversely affects patients' physical and mental health and overall quality of life but also results in significant socioeconomic burden. Current standard management strategies include allergen avoidance and pharmacological treatments such as oral and intranasal antihistamines, leukotriene receptor antagonists, and intranasal glucocorticoids. However, despite stepwise treatment approaches, a considerable proportion of patients continue to experience persistent symptoms and impaired quality of life, and may suffer from medication-related adverse effects, including drowsiness, dryness of the nasal or ocular mucosa, and nasal irritation.\n\nAllergen-specific immunotherapy is currently regarded as the only disease-modifying treatment for allergic rhinitis. Nevertheless, its long treatment duration, high cost, requirement for medical supervision, and variable patient response substantially limit accessibility and long-term adherence, particularly in low- and middle-income countries. In this context, there is an increasing need to identify adjunctive therapeutic approaches that are safe, effective, cost-efficient, and culturally acceptable.\n\nTraditional medicine has been widely applied in the management of allergic rhinitis in many countries, including Vietnam. Therapeutic modalities such as acupuncture, moxibustion, thread embedding therapy, and herbal medicine have been reported to alleviate symptoms, reduce recurrence rates, improve quality of life, and decrease reliance on pharmacological treatments.\n\nMoxibustion is a traditional therapeutic technique that applies heat generated by burning moxa sticks or moxa cones to specific acupuncture points, with the aim of regulating Qi and blood, strengthening vital energy, and enhancing the body's resistance to disease. This method is generally considered safe, easy to administer, low-cost, and suitable for implementation in community settings and primary health-care facilities. Several clinical studies worldwide have demonstrated that moxibustion can significantly improve symptoms of allergic rhinitis with a low incidence of adverse effects.\n\nHowever, high-quality scientific evidence regarding the efficacy and safety of moxibustion in the treatment of allergic rhinitis remains limited. In particular, there is a lack of well-designed and standardized randomized controlled trials. In Vietnam, although moxibustion is commonly used in traditional medicine practice, no clinical studies to date have systematically evaluated its effectiveness and safety in patients with allergic rhinitis. This gap in evidence highlights the need for rigorously designed clinical studies to strengthen the scientific basis, standardize treatment protocols, support the integration of moxibustion into clinical practice, and guide the development of integrative treatment models combining conventional medicine and traditional medicine in the management of allergic rhinitis.\n\nBased on these considerations, the present study is conducted to evaluate the efficacy and safety of moxibustion in the treatment of allergic rhinitis, with the aim of providing additional clinical evidence, improving treatment quality, and optimizing disease management for patients.",[28],[65],"Allergic rhinitis; Moxibustion; Mild moxibustion; Traditional medicine; Complementary therapy; Cold syndrome","2026-04-12",{"date":68,"type":42},"2026-04-17",{"date":70,"type":22},"2026-04-13",{"date":72,"type":22},"2026-10-01",{"name":74,"class":49},"University of Medicine and Pharmacy at Ho Chi Minh City",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100633923","phase-4-comparison-of-antihistamine-and-antileukotriene-add-on-therapy-to-intranasal-corticosteroid-in-allergic-rhinitis-100633923","NCT07532993","Comparison of Antihistamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in Allergic Rhinitis","Comparison of Intranasal Corticosteroid Plus Oral Antihistamine Versus Intranasal Corticosteroid Plus Oral Antileukotriene in Patients With Allergic Rhinitis","Inclusion Criteria:\n\n* Adults aged 18-60 years with a clinical diagnosis of allergic rhinitis.\n* Patients with moderate to severe symptoms (nasal obstruction, rhinorrhea, sneezing, itching).\n* Patients willing to participate and provide informed consent.\n* Patients not using antihistamines, antileukotrienes, or corticosteroids for at least 2 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Patients with bronchial asthma, chronic rhinosinusitis, nasal polyps, or significant nasal pathology.\n* Known hypersensitivity to study medications.\n* Pregnant or lactating women.\n* Use of systemic corticosteroids or immunotherapy within the past 4 weeks.\n* Active nasal or sinus infection.\n* Patients with significant systemic illness or unable to comply with follow-up.","50 Years",{"count":84,"type":22},32,[86],"PHASE4","Allergic rhinitis is a very common condition that can cause symptoms such as sneezing, a runny nose, nasal blockage, and itching in the nose. These symptoms can interfere with sleep, daily activities, and overall quality of life. Although several medicines are available to treat allergic rhinitis, it is not always clear which combination of treatments works best for patients in everyday clinical practice.\n\nThe purpose of this study is to compare two commonly used treatment combinations for allergic rhinitis in adults. One group of participants will receive an intranasal corticosteroid along with an oral antihistamine. The other group will receive an intranasal corticosteroid along with an oral antileukotriene. Both treatment approaches aim to reduce inflammation and improve symptoms, but they act through different pathways in the body.\n\nThis study is designed as a randomized controlled trial. Participants who meet the eligibility criteria will be assigned by chance to one of the two treatment groups. This method helps ensure that the comparison between treatments is fair and unbiased.\n\nThe main goal of the study is to find out whether one treatment combination provides better relief of nasal symptoms than the other, or if both treatments are equally effective. To assess this, participants' symptoms will be recorded using a structured symptom scoring system at the start of the study and during follow-up visits.\n\nParticipants will be evaluated at baseline and at scheduled follow-up visits. Changes in their symptoms over time will be carefully monitored and compared between the two groups. The results of this study may help doctors choose the most effective treatment approach for adults with allergic rhinitis and support better evidence-based care.\n\nThis study has been reviewed and approved by the institutional ethical review committee. Participation in the study is voluntary, and informed consent will be obtained from all participants before enrollment.",[28],"2026-04-09",{"date":91,"type":42},"2026-04-16",{"date":93,"type":22},"2026-09",{"date":95,"type":22},"2027-05",{"name":97,"class":49},"Liaquat National Hospital & Medical College",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":98},"100601810","effect-of-combined-probiotics-and-vitamin-d-on-symptoms-of-allergic-rhinitis-100601810","NCT07115342","Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis","Investigating Efficacy of Combined Probiotics and Vitamin D Supplementation in Reducing Symptoms and Improving Quality of Life in Patients With Allergic Rhinitis","Inclusion Criteria:\n\nConfirmed diagnosis of AR based on clinical history and specific IgE testing or will be screened for eligibility by the modified Mini Rhino-conjunctivitis Quality of Life Questionnaire (Mini RQLQ).\n\nPersistent rhinitis symptoms for at least two consecutive years.\n\nPresence of two or more AR symptom domains, including sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with symptoms persisting or accumulating for more than 1 hour daily with \\> 2 scores without taking medication.\n\nSymptoms may be accompanied by ocular manifestations such as eye itching, tearing, and redness\n\nVoluntarily and in writing, sign an informed consent form agreeing to participate in this study and able to complete the study as required by the trial protocol.\n\nVitamin D insufficiency or deficiency. Deficiency: \\\u003C 20 ng\u002FmL (\\\u003C 50 nmol\u002FL), Insufficiency: 20-29 ng\u002FmL (50-75 nmol\u002FL)\n\nExclusion Criteria:\n\nUse of systemic corticosteroids, immunosuppressive therapy, or medications affecting the gut microbiota (antimicrobials, probiotics, prebiotics, intestinal mucosal protective agents, etc.) within 4 weeks prior to screening.\n\nRegular use of probiotics, prebiotics, or vitamin D supplements within 6 months prior to screening.\n\nHistory of or concurrent use of medications or supplements that alter serum 25(OH)D levels, such as barbiturates, bisphosphonates, sulfasalazine, anticonvulsants, antiretrovirals, omega-3 supplements, or ketoconazole.\n\nDiagnosed with pulmonary tuberculosis, allergic asthma, chronic obstructive pulmonary disease (COPD), mast cell activation syndrome, or other respiratory diseases requiring treatment.\n\nCoexisting conditions such as nasal polyps, severe nasal septum deviation, severe gastrointestinal diseases (e.g., severe diarrhea or inflammatory bowel diseases), metabolic syndrome (e.g., obesity, dyslipidemia, hypertension, diabetes), or chronic systemic diseases or malignancies.\n\nHistory of autoimmune diseases or chronic inflammatory conditions.\n\nSinusitis, otitis media, or respiratory tract infections or upper respiratory infections within 14 days of the study start.\n\nKnown hypersensitivity or allergy to any component of the probiotics or other study interventions.\n\nPhysical signs or symptoms suggestive of renal, hepatic, or cardiovascular disease.\n\nPregnant or lactating women.","65 Years",{"count":108,"type":22},120,[25],"The goal of this clinical trial is to learn if taking probiotics, vitamin D, or both together can help lower symptoms of allergic rhinitis (AR) and improve quality of life in adults. Allergic rhinitis is a condition that causes sneezing, nasal congestion, and itchy or watery eyes.\n\nThe main questions this study aims to answer are:\n\n• Do these supplements improve the quality of life for people with AR?\n\nResearchers will compare four groups:\n\n* People taking probiotics and vitamin D\n* People receiving standard treatment only (control group)\n\nParticipants will:\n\n* Take a probiotic capsule daily and\u002For a vitamin D tablet (based on blood levels) for 12 weeks\n* Continue standard allergic rhinitis treatment (like antihistamines or nasal sprays)\n* Visit the clinic for checkups and lab tests\n* Complete surveys about their symptoms and quality of life\n\nThis study will help researchers understand if adding probiotics and\u002For vitamin D to standard care can help people with allergic rhinitis feel better.",[112,28],"Allergic Rhinitis",[114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,112],"Nutritional Supplementation","Integrative Medicine","Vitamin D Deficiency","T Regulatory Cells","Th2 Inflammation","Immune Response","Anti-inflammatory","Lactobacillus","Bifidobacterium","Gut Microbiota","Complementary Therapy","Combined Supplementation","Clinical Trial","Quality of Life","Nasal Symptoms","Immunomodulation","Vitamin D","Probiotics","RECRUITING","2025-08-10",{"date":135,"type":42},"2025-08-14",{"date":137,"type":42},"2025-08-01",{"date":139,"type":22},"2025-11-30",{"name":141,"class":49},"Tanta University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":17,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":98},"100569845","lacticaseibacillus-rhamnosus-lra05-for-alleviating-allergic-rhinitis-in-children-100569845","NCT06699537","Lacticaseibacillus Rhamnosus LRa05 for Alleviating Allergic Rhinitis in Children","Effectiveness of Lacticaseibacillus Rhamnosus LRa05 in Alleviating Allergic Rhinitis and Its Impact on Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily, in writing, sign the informed consent form, agreeing to participate in this study;\n2. Capable of completing the study according to the test protocol requirements;\n3. Age between 4 to 12 years old;\n4. Meet the diagnostic criteria for allergic rhinitis established in the \"Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (Revised Edition 2022)\";\n5. Symptoms: Presence of two or more symptoms such as sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than one hour per day, possibly accompanied by eye itching, tearing, and redness, and other ocular symptoms;\n6. Signs: Nasal mucosa is pale and edematous, possibly with watery secretions;\n7. Laboratory tests: At least one allergen detected by skin prick test and\u002For specific IgE positivity in serum;\n8. No use of antihistamines, corticosteroids, or immunosuppressants in the month before screening;\n9. No history of heart, liver, kidney, nervous system, mental disorders, or metabolic abnormalities.\n\nExclusion Criteria:\n\n1. Use of medications affecting the gut microbiota (including antimicrobial drugs, probiotics, intestinal mucosal protective agents, traditional Chinese patent medicines, etc.) for more than 1 week within 1 month prior to screening;\n2. Patients with coexisting pulmonary tuberculosis;\n3. Those with coexisting allergic asthma;\n4. Individuals with nasal polyps or severe nasal septal deviation;\n5. Patients with severe systemic diseases or malignant tumors;\n6. Those with congenital genetic diseases or congenital immunodeficiency diseases;\n7. Regular use of probiotics or prebiotics within 6 months prior to the screening period;\n8. Individuals with severe gastrointestinal diseases (including severe diarrhea, inflammatory bowel diseases, etc.);\n9. Those with metabolic syndrome (including obesity, dyslipidemia, hypertension, diabetes, etc.);\n10. Individuals with sinusitis, otitis media, or respiratory tract infections;\n11. Those allergic to any components of the probiotics used in this trial;\n12. Women who are pregnant or breastfeeding, or those planning to conceive in the near future;\n13. Subjects who discontinue the test sample or add other medications midway, making it impossible to determine efficacy or with incomplete information;\n14. Those who have recently consumed items similar to the test product, affecting the judgment of the results;\n15. Subjects who, due to their own reasons, cannot participate in the trial;\n16. Any other subjects deemed unsuitable to participate by the investigators.",true,"4 Years","12 Years",{"count":153,"type":22},70,[25],"The clinical trial aims to investigate the efficacy of Lactobacillus rhamnosus LRa05 in alleviating allergic rhinitis and its impact on the gut microbiota among 70 pediatric participants aged 4-12. The primary objective is to validate the improvement in allergic rhinitis symptoms following an 8-week intervention with Lactobacillus rhamnosus LRa05. Participants were instructed to consume the probiotic powder daily for approximately 8 weeks. At baseline, week 4, and week 8 endpoints, assessments of nasal symptoms, quality of life questionnaires, and stool samples for microbiota analysis were conducted on the participants, and blood samples were collected for immune-related factor testing.",[28],"2024-11-20",{"date":159,"type":42},"2024-11-21",{"date":161,"type":22},"2024-12-01",{"date":163,"type":22},"2025-12-01",{"name":165,"class":166},"Wecare Probiotics Co., Ltd.","INDUSTRY"]